3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
3
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Colorectal Neoplasms
28
Stomach Neoplasms
21
Pancreatic Neoplasms
14
Colonic Neoplasms
14
Rectal Neoplasms
9
Esophageal Neoplasms
8
Lymphoma, Large B-Cell, Diffuse
7
Adenocarcinoma Of Esophagus
7
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Cholangiocarcinoma
4
Adenocarcinoma
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Esophageal Squamous Cell Carcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Lymphoma, Follicular
2
Hepatoblastoma
2
Gastrointestinal Neoplasms
2
Gallbladder Neoplasms
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Unresectable Colorectal Cancer
1
Triple Negative Breast Neoplasms
1
Spinocerebellar Degenerations
1
Solid Cancer
1
Skin Neoplasms
1
Recurrence
1
Interventions
pembrolizumab
10
Cisplatin
8
Radiotherapy
6
Magnetic Resonance Spectroscopy
6
Carboplatin
6
Specimen Handling
5
Paclitaxel
5
Brachytherapy
5
Fluorodeoxyglucose F18
4
dostarlimab
3
atezolizumab
3
Trastuzumab
3
Radiation
3
Platinum
3
Nivolumab
3
Human Papillomavirus DNA Tests
3
Docetaxel
3
Colposcopy
3
1,2-diaminocyclohexaneplatinum II citrate
3
zimberelimab
2
tislelizumab
2
spartalizumab
2
olaparib
2
human papillomavirus vaccine, L1 type 16, 18
2
durvalumab
2
Vaccines
2
Surveys and Questionnaires
2
Standard of Care
2
Robotic Surgical Procedures
2
Radiotherapy, Intensity-Modulated
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Uterine Cervical Neoplasms
×
Oxaliplatin
×
Clear all
NCT05891171
2026-06-05
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled